Table 2.

Real-world progression free survival (months) by oncogenic mutation type (N = 1746)

	# Events/total N	Median rwPFS (95% CI)	6-month % PFS	12- month % PFS	HR (95% CI) *
Entire cohort	1423/1746	3.0 (2.8–3.1)	30.0	17.3	–
Mutation type
EGFR	406/458	2.5 (2.3–2.6)	17.8	8.1	Reference
ALK	58/65	2.3 (1.6–3.1)	24.1	11.2	0.89 (0.67–1.17)
BRAF	115/146	3.6 (2.6–4.7)	36.2	20.6	0.74 (0.59–0.91)
KRAS	844/1077	3.3 (3.0–3.6)	34.7	21.1	0.75 (0.66–0.85)

rwPFS Real-world progression free survival, CI confidence interval, HR hazard ratio

^*Cox regression model adjusted for sex, age, and line of therapy checkpoint inhibitor given